IKS Health subsidiary sells Abridge AI shares for USD 10 million

Strategic Transactions View source PDF Explain this filing

IKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.3%Reaction day

₹1884.00

prior close

₹1889.60

announcement price

In-mkt

timing

Nifty Smallcap 250market+0.2%-6.5% vs market

IT Enabled Services peers, median of 73sector-0.4%-6.0% vs sector

On the reaction day the stock moved 6.5 pts less than Nifty Smallcap 250 and 6.0 pts less than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.4

10m

-3.6

15m

-3.6

30m

-4.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.3+0.2-6.5-0.4-6.0

Next day

-7.7+0.2-7.8-0.4-7.3

-8.1+0.1-8.2-0.5-7.5

-7.2+0.3-7.6-0.9-6.4

-5.3+0.1-5.4-1.0-4.3

-5.4+0.2-5.7-1.2-4.2

-3.0-0.1-2.9-2.1-0.9

15d

-6.9+0.6-7.5-2.5-4.5

-5.2+0.9-6.1-3.3-2.0

-6.6-2.3-4.3-4.9-1.7

—————

UpDownMarket · Nifty Smallcap 250Sector · IT Enabled Services peers, median of 73Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IKS Health's US subsidiary IKS Inc has signed an agreement to sell 54,055 Series A-1 Preferred Shares in Abridge AI Inc to Alpha Square Group Fund IV, LP for USD 10,000,175 (about $10 million). The August 5, 2026 deal is a partial divestment or monetization of the firm's investment. Neither party is related to the company's promoters.

Likely market impact

Small cash inflow of about $10M from investment monetization; not material to core healthcare operations. Minor positive for shareholder value.